Summary by Moomoo AI
Assembly Biosciences, a biotechnology company focusing on the development of innovative therapeutics for serious viral diseases, has not reported any revenue from product sales and continues to operate at a loss due to significant research and development expenditures. The company's financial performance is characterized by an accumulated deficit of $785.7 million as of December 31, 2023, primarily from research and development and general and administrative expenses. Despite this, Assembly Biosciences has secured funding through equity financings and strategic collaborations, raising a total of $618.8 million in net proceeds and $185.7 million from upfront payments, respectively. The company's existing cash, cash equivalents, and marketable securities are expected to fund operations into the second half of 2025. In terms of business development, Assembly Biosciences has introduced...Show More